The remarkable features presented in this study include: 1) CXCL17-producing cells increased angiogenesis in vivo and formed tumors, 2) some of the human cancer cells expressed CXCL17, 3) they recruited immature CD11b+Gr-1+F4/80− myeloid-derived cells, and 4) the recruited myeloid-derived cells by CXCL17 could promote tumor growth in vivo. This evidence concerns the gene ITGAM and cancer.